Common Genetic Variants, QT Interval, and Sudden Cardiac Death in a Finnish Population-Based Study

Peter A. Noseworthy, MD*; Aki S. Havulinna, MSc*; Kimmo Porthan, MD; Annukka M. Lahtinen, MSc; Antti Jula, MD, PhD; Pekka J. Karhunen, MD; Markus Perola, MD, PhD; Lasse Oikarinen, MD, PhD; Kimmo K. Kontula, MD, PhD; Veikko Salomaa, MD, PhD; Christopher Newton-Cheh, MD, MPH

Methods and Results—We genotyped 15 common (minor allele frequency >1%) candidate single nucleotide polymorphisms (SNPs), based on association with the QT interval in prior studies, in individuals in two cohort studies (Health 2000, n=6597; Mini-Finland, n=801). After exclusions, we identified 116 incident SCDs from the remaining sample (n=6808). We constructed a QT genotype score (QTscore) using the allele copy number and previously reported effect estimates for each SNP. Cox proportional hazards models adjusting for age, sex, and geographical area were used for time to SCD analyses. The QTscore was a continuous independent predictor of the heart rate–corrected QT interval (P<10^{-17}). Comparing the top with the bottom quintile of QTscore, there was a 15.6-ms higher group mean QT interval (P<10^{-84}). A 10-ms increase in the observed QT interval was associated with an increased risk of SCD (hazard ratio, 1.19; 95% confidence interval, 1.07 to 1.32; P=0.002). There was no linear relationship between QTscore and SCD risk; although in post hoc secondary analysis there was increased risk in the top compared with the middle QTscore quintile (hazard ratio, 1.92; 95% confidence interval, 1.05 to 3.58; P=0.04).

Conclusions—Our study strongly replicates the relationship between common genetic variants and the QT interval and confirms the relationship between the QT interval and SCD but does not show evidence for a linear relationship between QTscore and SCD risk. (Circ Cardiovasc Genet. 2011;4:305-311.)

Key Words: death, sudden • genetics • QT interval • electrocardiography • mortality • electrophysiology
interval duration.\textsuperscript{11,13} Although individual common variants would be expected to result in only modest increments in SCD risk, these common variants could, in aggregate, increase SCD through influencing susceptibility to arrhythmogenic triggers such as myocardial ischemia, electrolyte disturbances, or QT-prolonging medications.

In this study, we studied a large, population-based cohort in Finland: (1) to attempt to replicate the association of these common genetic variants with QT interval, (2) to confirm the relationship between QT interval and SCD, and (3) to explore the association between a score reflecting the joint influence of the variants and the risk of SCD.

Methods

Study Population

The Health 2000 Study population is a cross-sectional cohort drawn from the Finnish Population Information System (http://www.vaestorikisterikeskus.fi/). The survey was carried out in Finland in 2000 to 2001. The implementation of the survey is described in detail elsewhere (http://www.terveys2000.fi/doc/methodologyrep.pdf).\textsuperscript{14} The study involved a 2-stage, stratified cluster sample representative of the whole adult Finnish population age $\geq$30 years. The Health 2000 sample comprised 8028 individuals, of whom 79% (6354 individuals; 2876 men and 3478 women) participated in a comprehensive health examination including questionnaires, measurements (eg, blood pressure, resting ECG), and physician’s physical examination. DNA samples were collected from 6597 subjects and digital ECGs were available from 6295 subjects.

The Mini-Finland Health Survey was carried out from 1978 to 1980.\textsuperscript{15} The study involved a 2-stage, stratified cluster sample representing the whole Finnish population aged 30 years or over. The sample size was 8000 individuals. Of the original sample, 1286 individuals living in 7 cities (Helsinki, Kuopio, Lahti, Oulu, Salo, Tampere, and Turku) were invited to a health reexamination in 2001, and 985 (77%) participated in the follow-up study. DNA samples were available from 801 subjects of the Mini-Finland Health Survey. Subjects $>$80 years old at baseline in either the Health 2000 or Mini-Finland study were excluded from the current investigation. For analysis of the association of the QT score with the observed QT interval, subjects were excluded if QT interval was not available, if the study ECG showed atrial fibrillation (n=55), QRS $\geq$120 ms (n=148), or if the subject was using QT-prolonging (n=1692) or QT-shortening (digoxin, n=90) medications. Subjects taking QT-altering medications were not excluded from analyses of the association of the QT score with SCD. A drug was considered to potentially prolong the QT interval if it was listed in any of the 4 categories in the list maintained at http://www.qtdrugs.org. Digoxin was classified as the sole QT-shortening medication. Mini-Finland participants were not included in analyses of QT interval because ECG intervals had not been measured.

Study Samples and Data Sources

Follow-up data were obtained using national active surveillance and health care registers in Finland. The National Causes-of-Death register (maintained by Statistics Finland) includes data on the underlying and immediate cause of death as well as up to 2 contributing causes of death for all deaths in Finland. The Finnish Hospital Discharge Register, maintained by the National Institute for Health and Welfare, includes date of admission, date of discharge, and diagnoses associated with admission. The National Drug Reimbursement Register, maintained by the National Social Insurance Institute, catalogues diagnosis codes submitted for medication reimbursement. All records were linked using personal ID codes, which are unique to each permanent resident of Finland. The follow up is 100% for all residents of Finland.

The Health 2000 and Mini-Finland Study protocols were approved by both the Institutional Ethics Committee and by the Epidemiology Ethics Committee of the Helsinki, and Uusimaa Hospital Region and carried out according to the recommendations of the Declaration of Helsinki.

Disease and Cause of Death Definitions

Cause of death was adjudicated by 2 independent physicians, based on information from Health 2000 and Mini-Finland examinations and the national registers: the National Causes-of-Death register, the Finnish Hospital Discharge Register that includes date of admission, date of discharge, and diagnosis associated with admission, and the National Drug Reimbursement Register. When the primary reviewers disagreed on the cause of death, cases were reviewed by 2 additional independent physicians, and a final adjudication was achieved by consensus. In total, 490 deaths were adjudicated. There was agreement in 439 of 495 (90%), and the remaining 51 cases were adjudicated with 2 additional reviewers. Adjudication of cause of death was blinded to genotyping data.

Deaths were adjudicated as probable SCD, possible SCD, unlikely SCD, and unknown cause of death. Eligible deaths for adjudication included out-of-hospital deaths and deaths within 10 days of hospitalization. Probable SCD was defined as a death in which a cardiac cause was listed as the immediate or underlying cause of death and death was not known to be unrelated to arrhythmia. Possible SCD was defined as a death in which the immediate or underlying cause of death was noncardiac, but cardiac disease was present and could reasonably have contributed to arrhythmia. Unknown cardiac cause of death included deaths for which insufficient data were available. We excluded deaths in individuals who had been hospitalized for more than 10 days before death. After exclusions, in total there were 84 probable sudden cardiac deaths, 32 possible sudden cardiac deaths, 347 unlikely sudden cardiac deaths, and 30 unknown etiology deaths. Probable and possible sudden cardiac deaths were pooled in the SCD analyses.

Autopsies were performed in 38.9% of all deaths, 62.6% of SCDs, and 73.0% of out-of-hospital SCDs. The median observational time was 8.1 years for Health 2000 and 7.8 years for Mini-Finland health.

Prevalent coronary heart disease (CHD) was defined as one of the following: (a) physician diagnosis during the survey health examination of previous MI or coronary disease requiring surgical or percutaneous revascularization; (b) previous hospital discharge with a diagnosis of MI (ICD-8 or ICD-9 code 410 or ICD-10 codes I21-I22); (c) pathological Q-waves or Minnesota code 1.1, 1.2 together with a QT-interval of 0.44 ms, or (d) history of coronary revascularization procedure in the hospital discharge records.

QT Interval

The QT interval was measured from 12-lead digital ECGs (recorded with Marquette MAC 5000, GE Marquette Medical Systems, Milwaukee, WI) using a validated automated algorithm.\textsuperscript{16} As previously reported,\textsuperscript{17} the QT interval from QRS onset to T-wave end was measured in each lead from the median QRS-T complex, which is a digitally averaged complex from the full 10-second recording and is automatically produced for each lead by the software (QT Guard, GE Marquette Medical Systems). In this study, the QT interval was defined as the mean of these 12 measurements. The QT intervals were corrected for heart rate using a validated nomogram-correction (QTnc) method.\textsuperscript{18} The nomogram-corrected QT interval=$\text{measured QT interval}+\{394.04 \text{ ms}-(\alpha \times \text{heart rate} + b)\}$, where “a” and “b” were determined separately for each 10 beats per minute heart rate range. Example: for heart rate 60 to 68 “a”=-2.18 and “b”=525.01 ms, for heart rate 69 to 78 “a”=-1.67 and “b”=489.94 ms (see online-only Data Supplement Table).
Genotyping
A total of 15 independent SNPs were reported in 2 genome-wide association studies11,13 to have genome-wide significant association with QT duration ($P<5 \times 10^{-8}$). Multiple SNPs at a given locus were included only if they were in low linkage disequilibrium with each other. Because the primary NOS1AP SNP is known to have a very strong effect and there is extensive linkage disequilibrium across the region, we only included the top SNP at NOS1AP. Genotyping of genomic DNA was performed using the Sequenom iPLEX Gold assay (MALDI-TOF mass spectrometry, MassARRAY Analyzer Compact, Sequenom Inc. San Diego, CA) according to the manufacturer’s instructions. Assays were designed using MassARRAY Assay Design 3.1 software. Sex markers were included in the iPLEX design for detection of plate swaps. Genotypes were automatically assigned and manually confirmed using MassARRAY TyperAnalyzer 4.0 software. Passing SNPs were required to have at least 80% genotyping success and Hardy-Weinberg equilibrium, $P>0.0001$; 1 SNP failed. Individuals with successful genotype calls for fewer than 8 of 14 SNPs were excluded from analyses.

Statistical Analysis
Three primary analyses were performed: (1) association between the QT genotype score ($QT_{score}$, see definition below) and the QT$_{NC}$ (2) observed QT$_{NC}$ as a predictor of SCD, and (3) QT$_{score}$ as a predictor of SCD.

A QT genotype score ($QT_{score}$) was constructed using the allele copy number and the previously established11,13 effect estimates for the 14 SNPs using the following formula: $QT_{score}=[(SNP1 allele copy number)\times(SNP1 effect estimate in predicted ms)]+[SNP2 allele copy number]\times(SNP2 effect estimate in predicted ms)]+\ldots$ through SNP14. SNP genotypes that were missing were imputed to have allele copy number equal to 2 times the coded allele frequency in the total sample. The genotype score was expressed in “predicted ms” of expected change in the QT interval.

All analyses included adjustment for age, sex, and geographic region. In analyses of SCD risk, additional adjustments were performed for use of QT-altering medications and prevalent CHD. To determine the referent quintile in these analyses, we first plotted the QT$_{NC}$ or QT$_{score}$ against SCD by decile (11 equal groups) to determine whether a nonlinear U- or J-shaped relationship existed. Multivariable linear regression models were used for cross-sectional association of genotype or QT$_{score}$ with QT$_{NC}$ and Cox proportional hazards models for association with time to SCD. Age was accounted for in the time scale of the Cox proportional hazards models for all SCD analyses. For single SNP to QT interval analyses, the threshold for significance was set at $P<0.007$ (0.05/14×2 for a 1-sided test of association in the same direction as the original report). For other primary analyses, significance was defined as 2-sided $P<0.05$; secondary analyses were exploratory.

Results
Demographic and clinical descriptive data for the total sample and SCD cases for Health 2000 and Mini-Finland are shown in Table 1.

### QT SNP Association With QT Interval
All SNPs but one (SNP rs17779747) were independently associated with QT interval in the same direction as in the QTGEN or QTSCD studies ($P<0.007$; Table 2). The correlation of effect estimates in Health2000 to the original QTGEN and QTSCD effect sizes was 0.99. The QT$_{score}$ weighted by the effect size observed in QTGEN and QTSCD was a continuous independent predictor of QT$_{NC}$ in a linear regression model after adjustment for age, sex, and geographic study region ($P<10^{-10}$; Figure 1). The mean QT$_{NC}$ in the top quintile was 15.6 ms higher than the bottom quintile ($P<10^{-84}$). The QT$_{score}$ explained 8.6% of variation in QT$_{NC}$, after adjustment for age, sex, and geographic study region.

### QT Interval as a Risk Factor for SCD
A 10-ms increase in QT$_{NC}$ was associated with an increased risk of possible or probable SCD in a Cox proportional hazards model after adjustment for sex and geographic study region (HR, 1.19; 95% confidence interval [CI], 1.07 to 1.32; $P=0.002$) and after additional adjustment for prevalent CHD and QT-altering medication use (HR, 1.07; 95% CI, 1.054 to 1.30; $P=0.003$). The relationship between QT$_{NC}$ and SCD appeared to be roughly linear across the range of QT$_{NC}$ quintiles (Figure 2). Results were unchanged using age- and sex-adjusted residuals (data not shown).

SCD risk was also assessed using a dichotomous previously reported threshold for QT prolongation (QT$_{NC}>450$ ms for men or >470 ms for women).9 The risk of SCD was 1.3% below and 24% above this threshold (HR, 13.3; 95% CI, 4.7 to 37.7; $P=1\times10^{-6}$, after adjustment for sex and geographic region; HR, 12.7; 95% CI, 4.2 to 38.6; $P=7\times10^{-6}$ after additional adjustment for prevalent CHD and QT-altering drugs). Significance testing using Fisher exact test without covariate adjustment was similar ($P=6\times10^{-6}$).

### QT$_{score}$ and Risk for SCD
None of the SNPs that contributed to the QT$_{score}$ were associated with SCD risk, when considered individually (Table 2). The continuous QT$_{score}$ as a predictor of possible or probable SCD showed a nonsignificant increase in SCD risk for increasing QT$_{score}$ (HR, 1.30 per 10 predicted milliseconds increase in QT$_{score}$; 95% CI, 0.87 to 1.94; $P=0.20$, after adjustment for sex and geographic region). Conditioning on identical exclusion

---

**Table 1. Demographic and Clinical Characteristics of Study Participants and SCD Cases in the Health 2000 and Mini-Finland Surveys**

<table>
<thead>
<tr>
<th></th>
<th>Entire Cohort</th>
<th>SCD Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Health 2000</td>
<td>Mini-Finland</td>
</tr>
<tr>
<td>Age y, mean±SD</td>
<td>52±13</td>
<td>63±8</td>
</tr>
<tr>
<td>Female, n</td>
<td>3261 (54%)</td>
<td>421 (59%)</td>
</tr>
<tr>
<td>Hypertension, n</td>
<td>2736 (45%)</td>
<td>459 (64%)</td>
</tr>
<tr>
<td>Dyslipidemia,* n</td>
<td>5214 (86%)</td>
<td>640 (89%)</td>
</tr>
<tr>
<td>Diabetes, n</td>
<td>479 (8%)</td>
<td>81 (11%)</td>
</tr>
<tr>
<td>Current smoker, n</td>
<td>1821 (30%)</td>
<td>117 (19%)</td>
</tr>
<tr>
<td>Coronary heart disease, n</td>
<td>233 (4%)</td>
<td>48 (7%)</td>
</tr>
<tr>
<td>QT prolonging meds, n</td>
<td>524 (9%)</td>
<td>62 (9%)</td>
</tr>
<tr>
<td>Digoxin, n</td>
<td>77 (1%)</td>
<td>13 (2%)</td>
</tr>
<tr>
<td>Heart rate, bpm, mean±SD</td>
<td>63±11</td>
<td>NA</td>
</tr>
<tr>
<td>QT ms, mean±SD</td>
<td>390±31</td>
<td>NA</td>
</tr>
<tr>
<td>QT$_{NC}$, ms, mean±SD</td>
<td>395±21</td>
<td>NA</td>
</tr>
</tbody>
</table>

*Dyslipidemia defined as LDL cholesterol >3.0 mmol/L, triglycerides >2.0 mmol/L, or HDL cholesterol <1.0 mmol/L in men or HDL cholesterol <1.2 mmol/L in women.
criteria applied to the QTnc to SCD analyses (ECG unavailable, >80 years old, presence of pacer, left bundle-branch block, right bundle-branch block, QRS >120, use of QT-prolonging drug, use of digoxin) did not change the finding.

In secondary post hoc analyses, the QTscore plotted against SCD by QTscore quintile suggested a U-shaped relationship (Figure 3) so the middle quintile was considered as the referent category. The risk of SCD was higher in the top QTscore quintile compared with the middle quintile (HR, 1.92; 95% CI, 1.05 to 3.58; \( P = 0.04 \) with adjustment for sex and geographic region; and HR, 1.90; 95% CI, 1.02 to 3.55; \( P = 0.04 \) with additional adjustment for CHD and QT-altering drugs).

**Table 2. Individual SNP Effects and Genotyping Success**

<table>
<thead>
<tr>
<th>Nearest Gene</th>
<th>Chr</th>
<th>Pos.*</th>
<th>SNP</th>
<th>Coded Allele</th>
<th>Cod. Freq.</th>
<th>Call Rate† (%)</th>
<th>HWE p</th>
<th>Effect, ms</th>
<th>SNP Versus QTnc</th>
<th>SNP Versus SCD</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP1B1</td>
<td>1q</td>
<td>167366107</td>
<td>rs10919071 A</td>
<td>0.89</td>
<td>99.5</td>
<td>0.70</td>
<td>3.3</td>
<td>7.5 ( \times 10^{-8} )</td>
<td>0.89</td>
<td>0.58</td>
</tr>
<tr>
<td>CNOT1/GINS3/NDRG4</td>
<td>16q</td>
<td>57124739</td>
<td>rs37062 A</td>
<td>0.74</td>
<td>99.7</td>
<td>0.059</td>
<td>2.4</td>
<td>1.0 ( \times 10^{-8} )</td>
<td>0.94</td>
<td>0.69</td>
</tr>
<tr>
<td>KCNE1</td>
<td>21q</td>
<td>34743550</td>
<td>rs1805128 A</td>
<td>0.01</td>
<td>100</td>
<td>0.09</td>
<td>10.4</td>
<td>9.0 ( \times 10^{-11} )</td>
<td>1.11</td>
<td>0.85</td>
</tr>
<tr>
<td>KCNH2</td>
<td>7q</td>
<td>150276467</td>
<td>rs1805123 A</td>
<td>0.82</td>
<td>95.7</td>
<td>0.34</td>
<td>2.6</td>
<td>1.3 ( \times 10^{-7} )</td>
<td>1.12</td>
<td>0.50</td>
</tr>
<tr>
<td>KCNH2</td>
<td>7q</td>
<td>150268796</td>
<td>rs4725882 T</td>
<td>0.28</td>
<td>99.8</td>
<td>0.84</td>
<td>2.0</td>
<td>2.4 ( \times 10^{-6} )</td>
<td>1.23</td>
<td>0.16</td>
</tr>
<tr>
<td>KCNJ2</td>
<td>17q</td>
<td>66006587</td>
<td>rs17779747 G</td>
<td>0.75</td>
<td>99.8</td>
<td>0.82</td>
<td>0.88</td>
<td>0.039</td>
<td>1.19</td>
<td>0.29</td>
</tr>
<tr>
<td>KCNO1</td>
<td>11p</td>
<td>2458895</td>
<td>rs12576239 T</td>
<td>0.16</td>
<td>99.9</td>
<td>0.56</td>
<td>2.6</td>
<td>4.6 ( \times 10^{-8} )</td>
<td>0.98</td>
<td>0.91</td>
</tr>
<tr>
<td>KCNO1</td>
<td>11p</td>
<td>2441379</td>
<td>rs2074238 C</td>
<td>0.91</td>
<td>100</td>
<td>0.24</td>
<td>6.3</td>
<td>1.9 ( \times 10^{-24} )</td>
<td>0.87</td>
<td>0.51</td>
</tr>
<tr>
<td>LITAF</td>
<td>16q</td>
<td>11601037</td>
<td>rs739551 G</td>
<td>0.58</td>
<td>99.2</td>
<td>0.13</td>
<td>1.4</td>
<td>1.6 ( \times 10^{-4} )</td>
<td>1.05</td>
<td>0.72</td>
</tr>
<tr>
<td>NOS1AP</td>
<td>1q</td>
<td>160300514</td>
<td>rs12143842 T</td>
<td>0.24</td>
<td>99.6</td>
<td>0.79</td>
<td>5.0</td>
<td>5.1 ( \times 10^{-31} )</td>
<td>1.26</td>
<td>0.12</td>
</tr>
<tr>
<td>PLN</td>
<td>6q</td>
<td>119100335</td>
<td>rs11756440 A</td>
<td>0.47</td>
<td>98.7</td>
<td>0.0002</td>
<td>1.9</td>
<td>1.2 ( \times 10^{-7} )</td>
<td>0.99</td>
<td>0.93</td>
</tr>
<tr>
<td>PLN</td>
<td>6q</td>
<td>118759897</td>
<td>rs12210810 G</td>
<td>0.97</td>
<td>100</td>
<td>0.22</td>
<td>3.6</td>
<td>5.9 ( \times 10^{-4} )</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td>RNF207</td>
<td>1p</td>
<td>6201957</td>
<td>rs846111 C</td>
<td>0.25</td>
<td>99.9</td>
<td>0.67</td>
<td>2.9</td>
<td>8.9 ( \times 10^{-12} )</td>
<td>1.29</td>
<td>0.08</td>
</tr>
<tr>
<td>SCN5A</td>
<td>3p</td>
<td>38568397</td>
<td>rs12053903 T</td>
<td>0.59</td>
<td>99</td>
<td>0.32</td>
<td>1.3</td>
<td>6.0 ( \times 10^{-4} )</td>
<td>1.02</td>
<td>0.89</td>
</tr>
</tbody>
</table>

Chr indicates chromosome; Pos, genome position; Cod. freq., coded allele frequency; and HWE, Hardy-Weinberg equilibrium.

SNP effects are represented as the change in QT (in ms) per copy of the coded allele (for SNP versus QTnc, selected based on a positive QT interval effect in the QTGEN or QTSCD publications, and HR for SCD per copy of the coded allele (for SNP versus SCD). Values represent the additive effect of each coded allele.

*SNP positions are shown in reference to National Center for Biotechnology Information reference sequence 36.

†Call rates are shown for each individual SNP after exclusion of individuals with <80% genotyping success for each genotyping pool separately.

‡HR estimated using Cox proportional hazards model with age as the time scale.

**Figure 1.** Observed difference in QTnc by QTscore quintile \( (n=1103 \text{ per quintile}) \) in comparison to the lowest quintile (Q1) and the predicted difference in QTnc. Error bars represent 95% CIs. Note, QTscore quintile includes exclusion for unavailable ECGs (ECG needed for QTnc calculation).

**Figure 2.** A graded relationship was observed between QTnc quintile \( (n=1175 \text{ subjects per quintile}) \) and HR for SCD after adjustment for sex, geographic region, prevalent CHD, and use of QT-altering medications. Error bars represent the 95% CIs of the HR for SCD.

**Discussion**

We strongly replicated the association between several recently identified common genetic variants and the QT interval, individually and in aggregate. We confirmed the relationship between the QT interval and SCD. There was no evidence for a linear relationship between QTscore and SCD risk. In post hoc analysis, there appeared to be increased SCD risk at fourth and fifth QTscore quintiles compared with the median quintile.

More generally, our findings support the strategy of studying common variants that contribute to a dichotomous trait by harnessing the relationship between common variants and an...
intermediate phenotype. It is well established that the rare mendelian diseases of extreme of QT duration, the long-QT syndrome and short-QT syndrome are risk factors for SCD, but this is the first illustration that multiple common variants that contribute to repolarization, together, may affect risk of SCD in the general population. Of note, none of the individual SNPs that constitute the score were independently associated with SCD, so they would not have been detectable in primary analyses based on association with SCD risk.

In the present study, the QT genotype score was highly associated with the observed QT interval, strongly replicating the findings of the QTGEN and QTSCD studies. In the QTGEN study, the top quintile of QT genotype score was associated with an approximately 9 to 12 ms higher QTc compared with nearly 16 ms in our study.

The strength of the QT score effect in our study in comparison to prior reports was somewhat surprising. One would typically expect to see smaller effects in a replication cohort than those observed in the discovery cohorts due to a tendency to overestimate effect sizes (“winner’s curse”) in initial discoveries. However, this bias is most pronounced for effects of borderline significance, whereas most discoveries in QTGEN and QTSCD greatly exceeded genome-wide significance thresholds.

The increased effect of QTscore on observed QT in our study may have resulted from more precise QT measurements and possibly more accurate adjustment for heart rate than in the prior studies. The measurement methods used in the Health 2000 have shown high reproducibility. Alternately, Finnish individuals may have a simpler genetic architecture, attributable to a founder effect resulting in loss of some rare variants with comparatively strong effect. The comparatively strong effects could also be due to chance alone.

Consistent with prior reports, prolonged QT interval was associated with increased risk of SCD. The QT interval was a continuous predictor of SCD risk across the range of QT intervals, but, most strikingly, there was a >10-fold increase in SCD risk above one published threshold for prolonged QT.

Despite QTscore being a strong predictor of QT interval, a significant linear relationship between the score and SCD was not observed (HR, 1.30 per 10 predicted millisecond increase in QTscore; 95% CI, 0.87 to 1.94; P=0.20). However, in exploratory analysis, the genotype-based QTscore was associated with an increased SCD risk in the fourth and fifth QTscore quintiles compared with the median quintile. The comparatively weak effect of the QT genotype score on SCD risk (compared with the QT interval itself) may result from lack of power, lack of true effect, or may arise because not all QT-prolonging alleles actually increase SCD risk. In future studies, the association of each individual SNP with SCD risk could be assessed, and a genotype-based score could be derived for SCD risk rather than QT effect, but this would need to be tested in an independent sample.

How might a QT genotype score offer additional risk prediction to the observed QT? Rather than simply reflecting the repolarization time, the QTscore may be a measure of susceptibility to arrhythmogenic stimuli. Uniform repolarization is maintained by multiple redundant mechanisms, a concept termed “repolarization reserve.” A single defect in one of these redundant pathways may reduce repolarization reserve but remain subclinical (and not reflected in the measured QT interval) until a “second hit” such as a drug exposure or myocardial ischemia unmasks the defect and provides the substrate for fatal arrhythmia. Indeed, many SCD cases in our study occurred on a background of risk factors for myocardial ischemia. The QTscore also may represent a subject’s lifelong exposure to genetically determined QT prolongation and may be more strongly associated with SCD than the QT interval measured in the resting, unperturbed state at one point in time.

Common variants in NOS1AP have been previously reported to be associated with the QT interval in individuals with congenital long-QT syndrome and more recently with SCD in unselected populations. Specifically, 2 independent signals have been associated with SCD: rs16847548, which is also associated with the QT interval, and rs12567209, which is associated with SCD only. The NOS1AP variant in our study (rs12143842) is correlated to rs16847548 (r²=0.818) but not to rs12567209 (r²=0.027). Though the NOS1AP SNP in our study did not reach statistical significance for association with SCD on its own (HR, 1.31; P=0.06), it has previously been shown to be associated with SCD with nearly identical HRs of 1.26 to 1.33. Of note, in prior studies, adjustment for QT interval attenuated but did not eliminate the association between rs16847548 and SCD, indicating that at least some of the effect of the rs16847548 (or its proxies) is mediated through its QT-prolonging effect.

Aside from these NOS1AP variants, relatively few common variants that contribute to SCD risk have been identified. Common SCD variants may be difficult to identify because SCD is a heterogeneous phenotype, representing the downstream end product of diverse underlying causes, case adjudication is challenging and often retrospective, and studies are underpowered because of the challenge of enrolling large SCD cohorts. The use of intermediate phenotypes can prove fruitful, as demonstrated by the relationship of common variants to low-density lipoprotein, which are also generally related to MI.

The methodologic advantages of this study are its use of large, population-based cohorts, prospective ascertainment of clinical data, a high rate of autopsies among SCD cases, and complete follow-up. The major limitations of this study are its low power to detect individual SNP effects due to small sample size,
possible survivor bias resulting from the older age at time of DNA collection in the Mini-Finland study, and imprecision in the case adjudication for SCD that relied on administrative data sources. Misclassification of noncardiac deaths as SCD could bias toward the null hypothesis of finding no association. Additionally, the SCD definition employed relies heavily on the presence of concomitant heart disease and thus may under-sample primary arrhythmic sudden deaths, a group in whom genetic causes are potentially more important. Last, not all QT prolongation is associated with increased SCD, such as that associated with amiodarone or ranolazine use. Analogously, it is possible that some variants that alter repolarization are arrhythmogenic while others are not.

In conclusion, our study strongly replicates the association between common genetic variants and the QT interval and suggests a relationship between these variants in aggregate and SCD. As additional QT interval variants are identified, these may add additional prognostic information to such genotype scores.

Acknowledgments

We thank Suzannah Bumpstead, Eija Hämäläinen, Kaisa Silander, Johannes Kettunen, and Antti-Pekka Sarin for help in the genotyping process.

Sources of Funding

This work was supported by the Max Schaldach Fellowship in Cardiac Pacing and Electrophysiology (Dr Noseworthy), a Burroughs Wellcome Fund travel grant (Dr Noseworthy), Finnish Academy SALVE program *Pugensense* (No. 10404) (Dr Perola), the Finnish Cultural Foundation (Dr Lahtinen), the Wellcome Trust, the Academy of Finland (Dr Kontula, and No 129494 to Dr Salomaa), the NIH/NHLBI (HL080025, HL098283, Dr Newton-Cheh), the Sigrid Juselius Foundation (Drs Kontula and Salomaa), the Academy of Finland (Drs Kontula, and No 129494 to Dr Salomaa), the Finnish Foundation for Cardiovascular Research (Drs Porthan, Kontula, Salomaa), the Sigrid Juselius Foundation (Drs Kontula and Salomaa), the NIH/NHLBI (HL080025, HL098283, Dr Newton-Cheh), the Doris Duke Charitable Foundation (Dr Newton-Cheh), and the Burroughs Wellcome Fund (Dr Newton-Cheh).

Disclosures

None.

References

Common Variants, QT, and SCD

There are more than 300,000 sudden cardiac deaths (SCDs) annually in the United States. Although there are known genetic syndromes that account for high sudden death risk in individuals, these account for only a small proportion of all sudden deaths. The current study sought to identify common genetic variants that contribute to SCD risk in the general population. The authors created a list of candidate variants that are known to be associated with electrocardiographic QT interval (an intermediate phenotypic for SCD) and analyzed a QT genotype score, based on the QT interval effect per allele copy number, summed over all variants. They validated the robust association between these variants in aggregate and the continuous QT interval duration in a multi-ethnic population. Further testing for the ability to improve SCD risk prediction will be necessary.
Common Genetic Variants, QT Interval, and Sudden Cardiac Death in a Finnish Population-Based Study

Peter A. Noseworthy, Aki S. Havulinna, Kimmo Porthan, Annukka M. Lahtinen, Antti Jula, Pekka J. Karhunen, Markus Perola, Lasse Oikarinen, Kimmo K. Kontula, Veikko Salomaa and Christopher Newton-Cheh

_Circ Cardiovasc Genet._ 2011;4:305-311; originally published online April 21, 2011; doi: 10.1161/CIRCGENETICS.110.959049

_Circulation: Cardiovascular Genetics_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2011 American Heart Association, Inc. All rights reserved.

Print ISSN: 1942-325X. Online ISSN: 1942-3268

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circgenetics.ahajournals.org/content/4/3/305

Data Supplement (unedited) at:

http://circgenetics.ahajournals.org/content/suppl/2011/04/21/CIRCGENETICS.110.959049.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Cardiovascular Genetics_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:

http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Cardiovascular Genetics_ is online at:

http://circgenetics.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL

**Supplementary table 1.** Nomogram-corrected QT interval

Nomogram-corrected QT interval = measured QT interval + correction value

correction value (ms) = 394.039219191961 – (a × heart rate + b)

<table>
<thead>
<tr>
<th>Heart rate (beats per minute)</th>
<th>a</th>
<th>b</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50</td>
<td>−2.92</td>
<td>564.69</td>
</tr>
<tr>
<td>51–59</td>
<td>−2.46</td>
<td>541.25</td>
</tr>
<tr>
<td>60–68</td>
<td>−2.18</td>
<td>525.01</td>
</tr>
<tr>
<td>69–78</td>
<td>−1.67</td>
<td>489.94</td>
</tr>
<tr>
<td>79–88</td>
<td>−1.57</td>
<td>481.89</td>
</tr>
<tr>
<td>89–98</td>
<td>−1.32</td>
<td>459.85</td>
</tr>
<tr>
<td>&gt;99</td>
<td>−1.68</td>
<td>494.69</td>
</tr>
</tbody>
</table>